Self-assembling ferritin nanoplatform for the development of infectious hematopoietic necrosis virus vaccine.

IHNV ZFL cells ferritin nanoparticles fish viruses macrophages protein stability self-assembling vaccine

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 29 11 2023
accepted: 09 01 2024
medline: 14 2 2024
pubmed: 14 2 2024
entrez: 14 2 2024
Statut: epublish

Résumé

Self-assembling protein nanoparticles are used as a novel vaccine design platform to improve the stability and immunogenicity of safe subunit vaccines, while providing broader protection against viral infections. Infectious Hematopoietic Necrosis virus (IHNV) is the causative agent of the WOAH-listed IHN diseases for which there are currently no therapeutic treatments and no globally available commercial vaccine. In this study, by genetically fusing the virus glycoprotein to the H. pylori ferritin as a scaffold, we constructed a self-assembling IHNV nanovaccine (FerritVac). Despite the introduction of an exogenous fragment, the FerritVac NPs show excellent stability same as Ferritin NPs under different storage, pH, and temperature conditions, mimicking the harsh gastrointestinal condition of the virus main host (trout). MTT viability assays showed no cytotoxicity of FerritVac or Ferritin NPs in zebrafish cell culture (ZFL cells) incubated with different doses of up to 100 µg/mL for 14 hours. FerritVac NPs also upregulated expression of innate antiviral immunity, IHNV, and other fish rhabdovirus infection gene markers (mx, vig1, ifit5, and isg-15) in the macrophage cells of the host. In this study, we demonstrate the development of a soluble recombinant glycoprotein of IHNV in the E. coli system using the ferritin self-assembling nanoplatform, as a biocompatible, stable, and effective foundation to rescue and produce soluble protein and enable oral administration and antiviral induction for development of a complete IHNV vaccine. This self-assembling protein nanocages as novel vaccine approach offers significant commercial potential for non-mammalian and enveloped viruses.

Identifiants

pubmed: 38352881
doi: 10.3389/fimmu.2024.1346512
pmc: PMC10863052
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1346512

Informations de copyright

Copyright © 2024 Ahmadivand, Krpetic, Martínez, Garcia-Ordoñez, Roher and Palić.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Sohrab Ahmadivand (S)

Faculty of Veterinary Medicine, Ludwig-Maximilians University Munich, Munich, Germany.

Zeljka Krpetic (Z)

Biomedical Research Centre, School of Science Engineering and Environment, University of Salford, Salford, United Kingdom.

Merce Márquez Martínez (MM)

Institute of Biotechnology and Biomedicine (IBB), Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.

Marlid Garcia-Ordoñez (M)

Institute of Biotechnology and Biomedicine (IBB), Universitat Autònoma de Barcelona, Barcelona, Spain.

Nerea Roher (N)

Institute of Biotechnology and Biomedicine (IBB), Universitat Autònoma de Barcelona, Barcelona, Spain.
CIBER de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain.

Dušan Palić (D)

Faculty of Veterinary Medicine, Ludwig-Maximilians University Munich, Munich, Germany.

Classifications MeSH